Divakar Vishwanath
Overview
Explore the profile of Divakar Vishwanath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim N, Vishwanath D, Basappa S, Kumar Harish K, Madegowda M, Rangappa K, et al.
Chem Biol Interact
. 2024 Oct;
404:111285.
PMID: 39442680
β-catenin is frequently implicated in signaling pathways that regulate autophagy, and the production of reactive oxygen species (ROS) has been linked to autophagy activation. Isoxazole-based nucleoside compounds have demonstrated anti-cancer...
2.
Kim N, Dukanya D, Sethi G, Girimanchanaika S, Yang J, Nagaraja O, et al.
Transl Oncol
. 2024 Aug;
49:102101.
PMID: 39159553
Small molecule-driven JNK activation has been found to induce apoptosis and paraptosis in cancer cells. Herein pharmacological effects of synthetic oxazine (4aS, 7aS)-3-((4-(4‑chloro-2-fluorophenyl)piperazin-1-yl)methyl)-4-phenyl-4, 4a, 5, 6, 7, 7a-hexahydrocyclopenta[e] [1,2]oxazine (FPPO;...
3.
Ravish A, Narasimhachar B, Xi Z, Vishwanath D, Mohan A, Gaonkar S, et al.
Biomedicines
. 2023 Oct;
11(10).
PMID: 37893090
Nuclear factor kappa B (NF-κB) is a potential therapeutic target in breast cancer. In the current study, a new class of oxazine- and piperazine-linked pyrimidines was developed as inhibitors of...
4.
Vishwanath D, Shete-Aich A, Honnegowda M, Anand M, Chidambaram S, Sapkal G, et al.
ACS Omega
. 2023 Aug;
8(30):27056-27066.
PMID: 37546653
The coronavirus (COVID-19) pandemic, along with its various strains, has emerged as a global health crisis that has severely affected humankind and posed a great challenge to the public health...
5.
Vishwanath D, Xi Z, Ravish A, Mohan A, Basappa S, Krishnamurthy N, et al.
Molecules
. 2023 Jul;
28(13).
PMID: 37446915
Histone deacetylases (HDACs) are an attractive drug target for the treatment of human breast cancer (BC), and therefore, HDAC inhibitors (HDACis) are being used in preclinical and clinical studies. The...
6.
Kim N, Vishwanath D, Xi Z, Nagaraja O, Swamynayaka A, Kumar Harish K, et al.
Molecules
. 2023 Apr;
28(8).
PMID: 37110684
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer exhibits early relapses, poor prognoses, and high recurrence rates. Herein, a JNK-targeting compound has been developed that may be of utility...
7.
Basappa B, Poonacha L, Xi Z, Vishwanath D, Yang J, Nagaraja O, et al.
Biomedicines
. 2023 Jan;
11(1).
PMID: 36672680
Small molecules are being used to inhibit cyclin dependent kinase (CDK) enzymes in cancer treatment. There is evidence that CDK is a drug-target for cancer therapy across many tumor types...
8.
Vishwanath D, Girimanchanaika S, Dukanya D, Rangappa S, Yang J, Pandey V, et al.
Molecules
. 2022 Feb;
27(3).
PMID: 35163965
Novel PARP inhibitors with selective mode-of-action have been approved for clinical use. Herein, oxadiazole based ligands that are predicted to target PARP-1 have been synthesized and screened for the loss...
9.
Barash U, Rangappa S, Mohan C, Vishwanath D, Boyango I, Basappa B, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34199150
Compelling evidence ties heparanase, an endoglycosidase that cleaves heparan sulfate side (HS) chains of proteoglycans, with all steps of tumor development, including tumor initiation, angiogenesis, growth, metastasis, and chemoresistance. Moreover,...